WHO confirms swine flu vaccine child narcolepsy concerns

Feb 08, 2011

Twelve countries have reported suspected cases of narcolepsy linked to swine flu jabs, the World Health Organisation said on Tuesday as its scientists said the findings warranted more investigation.

The WHO said in a statement that such sleep disorders, mainly in youngsters, had not been seen with vaccines in the past, and were more frequent in Sweden, Finland and Iceland than in other countries.

However, the UN health agency decided to keep its advice in favour of vaccination, including with the Pandemrix vaccine highlighted in the study, because it still felt the benefits outweighed a relatively small risk, spokeswoman Alison Brunier said.

Narcolepsy is a sleep disorder which causes extreme fatigue and often results in the patient falling soundly asleep without warning, even in the middle of an activity.

The Pandemrix vaccine made by GlaxoSmithKline was used in 47 countries worldwide during the 2009-2010, according to WHO, and was included by the agency in donations made to poor nations during the flu pandemic.

The WHO Global Advisory Committee on Vaccine Safety (GACVS) last week reviewed data from a Finnish study, which found that children injected with the Pandemrix flu vaccine were nine times more likely to contract narcolepsy than those who were not vaccinated.

"The committee agrees that further investigation is warranted concerning narcolepsy and vaccination against influenza (H1N1) 2009 with Pandemrix and other pandemic H1N1 vaccines," the WHO said.

"An increased risk of narcolepsy has not been observed in association with the use of any vaccines whether against influenza or other diseases in the past," it added.

The European Medicines Agency (EMA) has also launched a probe into the suspected connection.

"Since August 2010, following widespread use of vaccines against influenza (H1N1) 2009, cases of narcolepsy, especially in children and adolescents, have been reported from at least 12 countries," the WHO added.

Brunier noted that the EMA -- the regulatory body responsible for approving the vaccine -- had not taken any action. "There's no change to the WHO's current position on use of pandemic influenza vaccines," she added.

"This means that countries should continue vaccinating against H1N1 to immunise persons at risk of severe disease, using monovalent vaccines including Pandemrix if there is no trivalent seasonal vaccine available," she added.

Monovalent vaccines target a single strain of flu while trivalent vaccines, more commonly used every flu season, are effective against three strains.

The preliminary study by Finland's National Institute for Health and Welfare (THL) published a week ago said the most likely explanation of the pattern found in four to 19 year olds was the "joint effect of the vaccine and some other factor(s)."

It stressed that more investigation was needed.

Last August, THL recommended discontinuing its use against A(H1N1) until it could study the signs of a connection.

Explore further: New treatment approved for rare form of hemophilia

add to favorites email to friend print save as pdf

Related Stories

Swine flu vaccine likely causes child narcolepsy: study

Feb 01, 2011

Children injected with the Pandemrix swine flu vaccine were nine times more likely to contract narcolepsy than those who were not vaccinated, a preliminary study by Finland's National Institute for Health and Welfare, THL, ...

Sweden opens inquiry into suspect flu vaccine

Aug 18, 2010

Sweden's Medical Products Agency opened an inquiry Wednesday into vaccinations for swine flu made by British pharmaceutical company GlaxoSmithKline, suspected of provoking narcolepsy.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0